Foundation Medicine
FMI
Performance
About Foundation Medicine
Foundation Medicine is a precision oncology company focused on biomarker-driven cancer care, offering comprehensive genomic profiling and companion diagnostic tests to guide treatment decisions for patients. It provides a portfolio of diagnostic tests and biopharma services, including clinical development support and data-driven decision tools, with a global footprint and emphasis on EMR integrations to streamline clinical workflows. The company operates primarily in the United States, serving healthcare professionals, patients, and biopharma partners, and highlights resources such as a Knowledge Center and provider/patient education. Its tests, including FoundationOne CDx and FoundationOne Liquid CDx, aim to identify actionable genomic alterations to inform targeted therapies and immunotherapies.
Recent News
SOPHiA GENETICS Names Ross Muken CEO and Co Founder Camblong as Chairman Nominee
FDA Clears FoundationOne CDx as Companion Diagnostic for Tepotinib in MET‑Exon‑14 NSCLC
Assessing the Roche Acquisition of SAGA Diagnostics and the Future of Molecular Residual Disease Monitoring
Labcorp Expands Epic Pact to Make Full Test Menu Available on Aura
Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform
Recent Deals
No recent deals for this company.